Diamide-1,2-dioxide acrylic-and MTR-Everolimus inhibitors containing 2-acylpyridine-1,2-dioxide-1,2-methyl-5 (2-(2,2,2-trifluoro-1,1-dimethyl) pyridine-4-1-pyridine-4-acyl-amine were used to treat breast cancer; and drug syntheses were used. Use

摘要

The present invention relates to a pharmaceutical combination comprising a phosphatidylinositol-3-kinase (PI3K) inhibitor compound which is a 2-carboxamide cycloamino urea derivative or a pharmaceutically acceptable salt thereof and at least one mammalian target of rapamycin (mTOR) inhibitor or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising such a combination; and the uses of such a combination in the treatment proliferative diseases, more specifically of mammalian target of rapamycin (mTOR) kinase dependent diseases.